ES2153361T3 - Reactivos y procedimientos de cuantificacion de la totalidad de las doxepinas en fluidos biologicos. - Google Patents

Reactivos y procedimientos de cuantificacion de la totalidad de las doxepinas en fluidos biologicos.

Info

Publication number
ES2153361T3
ES2153361T3 ES92917171T ES92917171T ES2153361T3 ES 2153361 T3 ES2153361 T3 ES 2153361T3 ES 92917171 T ES92917171 T ES 92917171T ES 92917171 T ES92917171 T ES 92917171T ES 2153361 T3 ES2153361 T3 ES 2153361T3
Authority
ES
Spain
Prior art keywords
doxepin
quantification
reagents
doxepins
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92917171T
Other languages
English (en)
Inventor
Maciej Adamczyk
Jeffrey R Fishpaugh
Robert E Hruska
Donald Johnson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Application granted granted Critical
Publication of ES2153361T3 publication Critical patent/ES2153361T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02—Seven-membered rings
    • C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D313/12—[b,e]-condensed
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9466—Antidepressants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/815—Test for named compound or class of compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)

Abstract

SE PRESENTAN METODOS DE INMUNOENSAYOS Y REACTIVOS PARA LA CUANTIFICACION DEL TOTAL DE DOXEPINAS (POR EJEMPLO DOXEPINA E, DOXEPINA Z, DESMETILDOXEOPINA E Y DESMETILDOXEPINA) EN UNA MUESTRA DE PRUEBA. LA CUANTIFICACION DE DOXEPINAS SE REALIZA EN UN INMUNOENSAYO QUE EMPLEA ANTICUERPOS PREPARADOS CON DERIVADOS DE DOXEPINAS FORMULA (II), DONDE Y-Z PUDE SER C=C O N-CH2, R1 UN GRUPO DE ENLACE, R2 PUEDE SER H O CH3 Y Q PUEDE SER UNA UNIDAD DETECTABLE O UN MATERIAL PORTADOR INMUNOGENICO. EL REACTIVO DE ANTICUERPO COMPRENDE ANTICUERPOS QUE SON CAPACES DE ENLAZARSE AL TOTAL DE DOXEPINAS Y QUE SON PRODUCIDOS CON UNO O MAS INMUNOGENES PREPARADOS DEL DERIVADO DE DOXEPINA DE FORMULA (II), Y EL REACTIVO DE FORMULA (II), Y EL REACTIVO ETIQUETADO SE PREPARA TAMBIEN A PARTIR DE DOXEPINA DERIVADO DE FORMULA (II)
ES92917171T 1991-07-31 1992-07-29 Reactivos y procedimientos de cuantificacion de la totalidad de las doxepinas en fluidos biologicos. Expired - Lifetime ES2153361T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73840091A 1991-07-31 1991-07-31
US07/916,066 US5332661A (en) 1991-07-31 1992-07-24 Reagents and methods for the quantification of total doxepins in biological fluids

Publications (1)

Publication Number Publication Date
ES2153361T3 true ES2153361T3 (es) 2001-03-01

Family

ID=27113357

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92917171T Expired - Lifetime ES2153361T3 (es) 1991-07-31 1992-07-29 Reactivos y procedimientos de cuantificacion de la totalidad de las doxepinas en fluidos biologicos.

Country Status (9)

Country Link
US (2) US5332661A (es)
EP (1) EP0641440B1 (es)
JP (1) JP3071824B2 (es)
AT (1) ATE197508T1 (es)
AU (1) AU2420692A (es)
CA (1) CA2111467C (es)
DE (1) DE69231559T2 (es)
ES (1) ES2153361T3 (es)
WO (1) WO1993003372A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0578292A (ja) * 1991-04-05 1993-03-30 Hokuriku Seiyaku Co Ltd 三環系化合物
US5686237A (en) 1995-06-05 1997-11-11 Al-Bayati; Mohammed A. S. Use of biomarkers in saliva to evaluate the toxicity of agents and the function of tissues in both biomedical and environmental applications
US5804395A (en) * 1995-12-01 1998-09-08 The United States Of America As Represented By The Secretary Of The Navy Fluorescence polarization assays of enzymes and substrates therefore
US20090042971A1 (en) * 2006-05-19 2009-02-12 Somaxon Pharmaceuticals, Inc. Method of using low-dose doxepin for the improvement of sleep
WO2007136741A2 (en) * 2006-05-19 2007-11-29 Somaxon Pharmaceuticals, Inc. N-desmethyl-doxepin and methods of using the same to treat sleep disorders
CA2687118A1 (en) 2006-05-19 2007-12-13 Somaxon Pharmaceuticals, Inc. Methods of using low-dose doxepin for the improvement of sleep
US20090042972A1 (en) * 2006-05-19 2009-02-12 Somaxon Pharmaceuticals, Inc. Methods of using low-dose doxepin for the improvement of sleep
US20080058408A1 (en) * 2006-05-19 2008-03-06 Rogowski Roberta L Low-dose doxepin for treatment of sleep disorders in elderly patients
US20100179215A1 (en) * 2006-05-19 2010-07-15 Somaxon Pharmaceuticals, Inc. Doxepin isomers and isomeric mixtures and methods of using the same to treat sleep disorders
US20100179214A1 (en) 2006-05-19 2010-07-15 Somaxon Pharmaceuticals, Inc. Doxepin trans isomers and isomeric mixtures and methods of using the same to treat sleep disorders
WO2008011150A1 (en) 2006-07-20 2008-01-24 Somaxon Pharmaceuticals, Inc. Methods of improving the pharmacokinetics of doxepin
US20080182890A1 (en) * 2006-10-04 2008-07-31 Somaxon Pharmaceuticals, Inc. Methods of using low-dose doxepin for the improvement of sleep
WO2008052139A2 (en) 2006-10-25 2008-05-02 Somaxon Pharmaceuticals, Inc. Ultra low dose doxepin and methods of using the same to treat sleep disorders
WO2008070795A2 (en) 2006-12-06 2008-06-12 Somaxon Pharmaceuticals, Inc. Combination therapy using low-dose doxepin for the improvement of sleep
WO2008128115A2 (en) 2007-04-13 2008-10-23 Somaxon Pharmaceuticals, Inc. Low-dose doxepin formulations
WO2010080577A2 (en) * 2008-12-18 2010-07-15 Auspex Pharmaceutical, Inc. Oxepine modulators of h1 receptors and/or inhibitors of mast cell degranulation
US11119098B2 (en) 2014-10-31 2021-09-14 Massachusetts Institute Of Technology Systems including Janus droplets
US10060913B2 (en) * 2016-09-19 2018-08-28 Massachusetts Institute Of Technology Systems including janus droplets capable of binding an analyte and changing orientation to provide a detectable change
WO2016070027A1 (en) 2014-10-31 2016-05-06 Massachusetts Institute Of Technology Compositions and methods for arranging colloid phases
US10252231B2 (en) 2014-10-31 2019-04-09 Massachusetts Institute Of Technology Compositions and methods for forming emulsions
US20190170737A1 (en) 2016-09-19 2019-06-06 Massachusetts Institute Of Technology Systems including janus droplets
CN112159385A (zh) * 2020-09-25 2021-01-01 武汉爱民制药股份有限公司 一种去甲基盐酸多塞平的合成方法
CN115326987A (zh) * 2022-08-31 2022-11-11 内蒙古帕默康创医疗仪器有限公司 多塞平血药浓度检测方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4223013A (en) * 1978-12-29 1980-09-16 Syva Company Amitriptyline conjugates to antigenic proteins and enzymes
US4420568A (en) * 1980-07-30 1983-12-13 Abbott Laboratories Fluorescent polarization immunoassay utilizing substituted triazinylaminofluoresceins
US4495281A (en) * 1982-10-21 1985-01-22 Miles Laboratories, Inc. Tricyclic antidepressant drug immunogens, antibodies, labeled conjugates, and related derivatives
US4629691A (en) * 1983-08-01 1986-12-16 Syntex (U.S.A.) Inc. Tricyclic antidepressant conjugates with antigens and enzymes
EP0226730B1 (en) * 1985-10-15 1994-03-02 Abbott Laboratories Compounds and assay for tricyclic antidepressants
US4704867A (en) * 1985-12-09 1987-11-10 Allied Corporation Hydraulic brake booster with cam and lever ratio changer
GB9001694D0 (en) * 1990-01-25 1990-03-28 Therapeutic Antibodies Inc Immunogenic compositions
US5413911A (en) * 1990-12-14 1995-05-09 Abbott Laboratories Determination of tricyclic antidepressant drugs in the presence of interfering substances

Also Published As

Publication number Publication date
CA2111467A1 (en) 1993-02-18
JPH06509797A (ja) 1994-11-02
DE69231559T2 (de) 2001-06-21
JP3071824B2 (ja) 2000-07-31
WO1993003372A1 (en) 1993-02-18
CA2111467C (en) 2002-11-12
US5332661A (en) 1994-07-26
AU2420692A (en) 1993-03-02
EP0641440A4 (en) 1996-04-10
ATE197508T1 (de) 2000-11-11
EP0641440B1 (en) 2000-11-08
DE69231559D1 (de) 2000-12-14
US5464767A (en) 1995-11-07
EP0641440A1 (en) 1995-03-08

Similar Documents

Publication Publication Date Title
ES2153361T3 (es) Reactivos y procedimientos de cuantificacion de la totalidad de las doxepinas en fluidos biologicos.
DE3851967D1 (de) Verfahren zur Bestimmung von Antikörpern.
CA2014318A1 (en) Reagents, methods and kits for an amphetamine-class fluorescence polarization immunoassay
KR910020438A (ko) 다수염소화된 비페닐을 검출하기 위한 시약 및 방법
ATE102948T1 (de) Neue digoxigenin-derivate und ihre verwendung.
FI891012A (fi) Menetelmä ja väline immuunikokeissa esiintyvien häiriötekijöiden kompensoimiseksi
ATE37095T1 (de) Fluoreszenz-untersuchungsverfahren zur bluttypenbestimmung.
ATE74663T1 (de) Quadratfarbstoffkonjugat, dessen herstellungsverfahren und dessen verwendung bei testverfahren sowie testsaetze.
DE69609108D1 (de) Verbesserte Immunoessayreagenzien zum Nachweis von Kannabinoiden
ATE74662T1 (de) Immunoanalysetestverfahren fuer cholesterolepoxide.
ES2079368T3 (es) Metodo y reactivos para detectar anfetaminas y/o d-meta-anfetaminas en muestras biologicas.
NO874140D0 (no) Immunometriske bestemmelsesfremgangsmaater.
KR930703290A (ko) 코티닌 면역검정용 합텐, 트레이서, 면역원 및 항체
DK314886D0 (da) Histamin-derivat og -immunogen-konjugat, cellelinie og antistof produceret deraf samt immunbestemmelse af histamin ved hjaelp af antistoffet
ATE200353T1 (de) Kompetitiver immuntest unter verwendung komplexierter analytderivate
EP0641439A4 (en) REAGENTS AND METHODS FOR QUANTIFYING IMIPRAMINE OR DESIPRAMINE IN BIOLOGICAL FLUIDS.
ES2152229T3 (es) Reactivos y procedimientos de cuantificacion de la amitriptilina o de la nortriptilina en fluidos biologicos.
DE69922680D1 (de) Detektion und quantifikation von vancomycin in den biologischen flüssigkeiten
ATE286596T1 (de) Chemische modifikation von antikörpern und antigenen
CA2114327A1 (en) Haptens, tracers, immunogens and antibodies for immunoassays for propoxyphene
WO1997024621A3 (en) Reagents for measuring lead levels via the quantification of porphobilinogen
SE9303272D0 (sv) Improvement in immunoassays

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 641440

Country of ref document: ES